✦ LIBER ✦

Caution in the interpretation of safety and efficacy differences in clinical trials comparing aminosalicylates for ulcerative colitis

✍ Scribed by Stephen B. Hanauer

Book ID: 119393816
Publisher: Nature Publishing Group
Year: 2003
Tongue: English
Weight: 40 KB
Volume: 98
Category: Article
ISSN: 0002-9270
DOI: 10.1016/s0002-9270(02)05873-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clinical trial: five or ten cycles of gr

Clinical trial: five or ten cycles of granulocyte–monocyte apheresis show equivalent efficacy and safety in ulcerative colitis

✍ A. U. DIGNASS; A. ERIKSSON; A. KILANDER; A. PUKITIS; J. M. RHODES; S. VAVRICKA 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 181 KB

Clinical trial: randomized-controlled cl

Clinical trial: randomized-controlled clinical study comparing the efficacy and safety of a low-volume vs. a high-volume mesalazine foam in active distal ulcerative colitis

✍ R. ELIAKIM; Z. TULASSAY; L. KUPCINSKAS; K. ADAMONIS; J. POKROTNIEKS; S. BAR-MEIR 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 224 KB

Randomised clinical trial: the efficacy

Randomised clinical trial: the efficacy and safety of propionyl-l-carnitine therapy in patients with ulcerative colitis receiving stable oral treatment

✍ T. L. Mikhailova; E. Sishkova; E. Poniewierka; K. P. Zhidkov; I. G. Bakulin; L. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 325 KB

A Review of Activity Indices and Efficac

A Review of Activity Indices and Efficacy End Points for Clinical Trials of Medical Therapy in Adults With Ulcerative Colitis

✍ Geert D’Haens; William J. Sandborn; Brian G. Feagan; Karel Geboes; Stephen B. Ha 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 302 KB

Clinical trial: controlled, open, random

Clinical trial: controlled, open, randomized multicentre study comparing the effects of treatment on quality of life, safety and efficacy of budesonide or mesalazine enemas in active left-sided ulcerative colitis

✍ F. Hartmann; J. Stein; the BudMesa-Study Group 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 260 KB

Optimal apheresis treatment volume for t

Optimal apheresis treatment volume for the efficacy and safety of leukocytapheresis with cellsorba in patients with active ulcerative colitis

✍ Ken Fukunaga; Koji Kamikozuru; Yoko Yokoyama; Nobuyuki Hida; Yoshio Ohda; Naohis 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 165 KB

## Abstract **Background**: Leukocytapheresis (LCAP) is used as an adjunct therapy for patients with active ulcerative colitis (UC). Although, LCAP is routinely performed at 3,000 mL per session, we were interested to see that if this can be replaced with bodyweight (BW) adjusted volume. **Methods*